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Objective: To compare cardiometabolic risk factors including cytokine and adipokine
concentrations between individuals with and without back pain.
Methods: In 62 overweight/obese adults (BMI≥ 25 kg/m2; 23F/39M), we collected data
on: self-reported back pain; anthropometry [BMI, waist circumference, body composition
(dual energy X-ray absorptiometry—DEXA)]; metabolic parameters [fasting glucose;
insulin sensitivity (hyperinsulinaemic-euglycaemic clamps)]; cardiovascular parameters
(blood pressure, lipids); serum inflammation markers [high-sensitivity C-reactive protein
(hsCRP; immunoturbidimetric-assay), tumor necrosis factor-alpha (TNF-α), interleukin
(IL)-6, and IL-10 (multiplex-assay)]; and adipokines [leptin, adipsin, resistin, and
adiponectin (multiplex-assay)].
Results: Participants who reported having back pain in the past month (n = 24; 39%)
had higher BMI (mean ± SD = 33.8 ± 6.3 vs. 30.2 ± 4.1 kg/m2, p = 0.008), fat-mass
(39.9 ± 12.3 vs. 33.9 ± 9.8%, p = 0.04), and waist circumference (109.6 ± 16.8
vs. 101.0 ± 9.3 cm, p = 0.01) compared to those without back pain (n = 38; 61%).
No differences were observed in cardiometabolic parameters, inflammatory markers, or
adiponectin or resistin concentrations. Those reporting back pain had higher adipsin
concentrations compared to those without back pain [median (IQR) = 744 (472–2,804)
vs. 721 (515–867) ng/ml, p = 0.03], with a trend for higher leptin [5.5 (1.5–24.3) vs.
2.3 (1.5–6.7) ng/ml, p = 0.05], both of which persisted after adjustment for age and
sex. Adipsin remained associated with back pain independently of adiposity (BMI, waist,
fat-mass, or total %body fat; all p ≤ 0.03).
Conclusions: Greater obesity, and higher adipsin and leptin concentrations were
observed in those who reported back pain in the past month compared to those without
back pain, and adipsin was associated with back pain independently of adiposity. Larger
studies are needed to determine if adipsin could be a novel therapeutic target for
prevention and/or treatment of back pain.
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INTRODUCTION
Back pain causes greater disability worldwide than any other
condition (Hoy et al., 2014), resulting in a considerable global
health and financial burden (Katz, 2006). Given that there are few
effective treatments for back pain (Maher et al., 2017), primary
prevention strategies aiming to reduce risk factors for back pain
are critical. Obesity is a potential risk factor for the development
of back pain (Brady et al., 2017); however, it is unclear whether
this is due to physical loading on spinal structures or systemic
factors. Previous studies have shown that back pain intensity and
associated disability are related to increased fat mass, but not
muscle mass (Urquhart et al., 2011), raising the possibility that
there may be systemic factors at play.
Other cardiometabolic risk factors may also contribute to
the pathophysiology of back pain, including components of the
metabolic syndrome such as hypertension, dyslipidaemia, and
raised fasting blood glucose (Ranasinghe et al., 2017), but also
more novel markers such as markers of inflammation (Johnson
et al., 2015) and adipokines (Gomez et al., 2009). In fact,
osteoarthritis has recently been labeled a metabolic disorder
(Mobasheri et al., 2017), with some studies suggesting that
cardiometabolic risk factors may increase risk of osteoarthritis
independently of obesity (Wang et al., 2016), by dysregulating
metabolic signaling, increasing oxidative stress and endothelial
dysfunction, and via cholesterol accumulation in cartilage which
impairs its eﬄux functions (Wang et al., 2016).
It is also proposed that pain in osteoarthritis occurs via
inflammatory mechanisms (Mobasheri et al., 2017) with a
potential role for adipokines (Martel-Pelletier et al., 2016).
Adipose tissue secretes many different substances, including
cytokines, such as interleukins (IL), tumor necrosis factor-
alpha (TNF-α), and adipokines such as adiponectin, leptin,
and adipsin (Pottie et al., 2006; Robinson et al., 2009). These
inflammatory markers and adipokines may represent future
therapeutic targets (Johnson et al., 2015). Indeed, leptin has
been proposed as a possible causative link between obesity and
osteoarthritis (Vuolteenaho et al., 2014; Martel-Pelletier et al.,
2016), while TNF-α and ILs-6 and−8 have been implicated in
structural joint abnormalities (Dumond et al., 2003), nociceptive
pathways (Lübbeke et al., 2013), and in the development and
progression of chronic pain (Dina et al., 2008; Wang et al.,
2008). However, previous studies are limited by small sample
sizes and/or inclusion of patients with existing osteoarthritic
diseases or who were undergoing surgery (Wang et al., 2008;
Kraychete et al., 2010; Queiroz et al., 2015). To our knowledge,
no studies have explored novel adipokines such as adipsin or
resistin in relation to back pain, and inconsistent findings have
been reported for relationships between back pain and other
adipokines such as leptin and adiponectin (Shiri et al., 2008;
Lippi et al., 2017). Consequently, important knowledge gaps
remain regarding whether cardiometabolic risk factors including
inflammatory markers and adipokines contribute to back pain,
particularly in high-risk groups such as overweight or obese
adults.
We aimed to address this knowledge gap by examining
relationships between back pain and cardiometabolic risk
factors including cytokines and adipokines in a metabolically
well-characterized cohort, using gold-standard measurements
of adiposity and insulin sensitivity. Specifically, we aimed
to determine whether overweight or obese individuals with
back pain within the past month had poorer cardiometabolic
profiles and/or unfavorable concentrations of cytokines and/or
adipokines compared to individuals without back pain.
MATERIALS AND METHODS
Design and Participants
This cross-sectional study utilizes baseline data from a previous
randomized controlled trial (RCT) which examined the effects of
vitamin D supplementation on insulin sensitivity in overweight
or obese adults, with methods reported previously (de Courten
et al., 2015). Briefly, volunteers were recruited from the
community using online and poster advertising in Melbourne,
Australia, and were included if they were adults aged 18–60
years with a BMI ≥ 25 kg/m2 and a stable weight (<5 kg
change in preceding year). Participants were not selected based
on back pain status, and were excluded if they were smokers, had
high alcohol consumption, or used any medications (including
pain medications), vitamins, or supplements. Participants with
hypercalcaemia, allergies, diabetes, or any medical condition,
central nervous system or psychiatric disorders, active cancer
within the preceding 5 years, or the presence of acute
inflammation were excluded. Pregnant, lactating, or peri/post-
menopausal women were excluded. The study was carried out
in accordance with the recommendations of the Declaration of
Helsinki with written informed consent from all participants.
The protocol was approved by the Monash University Human
Research Ethics Committee (CF13/3874-2013001988).
Self-Reported Measures Including Back
Pain
All measurements were performed at three visits attended over 1
week. At the first visit, participants underwent a medical history
and examination which included the question “Have you had
back pain in the past month?” Participant responses as “yes”
or “no,” were recorded and used to determine back pain status
in the present study. Data on physical activity was collected
using the validated International Physical Activity Questionnaire
(IPAQ), which calculates multiples of the resting metabolic
rate (METs) to characterize the level of exercise intensity,
wherein a single MET represents the energy utilized by the body
at rest.
Anthropometric and Cardiometabolic
Assessments
Body mass index (BMI) was also calculated at the first visit using
weight (kg)/height (m)2, and waist circumference was measured
as an additional measure of central obesity. At the second
visit, dual energy X-ray absorptiometry (DEXA) scans, the gold-
standard measure of adiposity, were performed to determine
body fat composition as total percentage body fat. Total body fat
was then used to calculate fat mass [weight (kg) × total % body
fat (decimal) = fat mass (kg)] as well as fat-free mass [weight
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(kg) – fat mass (kg) = fat-free mass (kg)]. Resting systolic and
diastolic blood pressure (SBP, DBP) weremeasured after a 20-min
rest, using an automated oscillometric measurement system (M6
Automatic BP monitor, Omron, Japan), and the average of three
measurements was recorded. Insulin sensitivity was measured
at the third visit using the gold-standard hyperinsulinaemic-
euglycaemic clamp as previously described (de Courten et al.,
2015).
Biochemical Analyses
Fasting venous blood samples were collected and analyzed
under blinded conditions by an accredited and quality-assured
laboratory (Monash Health Pathology, Melbourne). Serum
triglycerides, and total, low-, and high-density lipoprotein
(LDL/HDL) cholesterol were measured using commercial
enzymatic assays with inter- and intra-assay CVs < 8%
(LX20PRO Analyser, SYNCHRON Multi-calibrators; Beckman
Coulter Inc., Sydney, Australia). Fasting blood glucose was
measured after a 12 h overnight fast using the glucose oxidase
method (YSI-2300 STAT; YSI Inc., OH, USA).
High sensitivity C-reactive protein (hsCRP) concentrations
were measured using highly sensitive near-infrared particle
immunoassay on a Synchron LX System Analyser according to
manufacturer’s instructions (Beckman Coulter Inc., Sydney,
Australia), with inter- and intra-assay CVs of <3 and
<5%, respectively. Inflammatory markers and adipokines
were measured using bead-based multi-analyte assays
(LEGENDplexTM Human Inflammation and Human Metabolic
Panels; Biolegend, San Diego, CA). These panels simultaneously
quantified pro- and anti- inflammatory markers including
TNF-α, IL-6, and IL-10, and adipokines including leptin,
adiponectin, adipsin, and resistin. Data were analyzed using the
LEGENDplexTM Data Analysis Software (BioLegend, San Diego,
CA) with standard curves generated from 0 to 50,000 pg/ml for
inflammatory markers and 0 to 200 ng/ml for adipokines, and
samples adjusted for dilution factors. Inter- and intra-assay CVs
for all analytes were <8 and <9%, respectively.
Statistical Analyses
Data for this study was derived from a previous RCT where the
sample size calculation has been reported elsewhere (de Courten
et al., 2015), and was based on insulin sensitivity as the primary
outcome. Results are presented as mean ± standard deviation
(SD) or median (interquartile range) unless otherwise specified.
Normality was assessed by visual inspection of histograms
and Shapiro-Wilk tests and non-normally distributed variables
were transformed as appropriate (logarithmic or square root
transformations) to approximate normality prior to analyses.
Independent samples t-tests and chi-squared tests were used
to compare continuous and categorical variables, respectively,
between those with and without back pain. Multivariable
logistic regression was used to examine differences between
those with and without back pain after adjusting for clinically
relevant variables including age, sex, and measures of adiposity.
Interaction terms for gender were added to the multivariable
models to examine whether differences between groups (back
pain vs. no back pain) varied by gender. Findings were considered
statistically significant at a two-tailed level of P < 0.05.
All analyses were performed using Stata V.13 (StataCorp,
TX, USA).
RESULTS
Sample Characteristics
Sixty-two participants (39 males/23 females) were included in
the analysis, with a mean age of 31.3 ± 8.5 years and a mean
BMI and total % body fat of 31.6 ± 5.3 kg/m2 and 40.2 ± 8.7%,
respectively. There were no differences between genders in age
(p = 0.6) or BMI (p = 0.08), however, females had a higher total
% body fat (49.0 ± 5.5 vs. 35.3 ± 5.8%, respectively, p < 0.001)
and higher fat mass (40.5 ± 8.0 vs. 33.7 ± 11.9 kg, respectively,
p = 0.02) than males, while males had a higher fat-free mass
(60.0 ± 10.5 vs. 41.7 ± 5.7 kg, respectively, p < 0.001). Males
had an overall poorer cardiometabolic profile, with higher fasting
glucose concentrations (4.7± 0.5 vs. 4.4± 0.5 mmol/l, p= 0.03),
SBP (125.1 ± 12.1 vs. 115.4 ± 2.2 mmHg, p = 0.002), and
triglycerides (1.8± 1.0 vs. 1.2± 0.4 mmol/l, p= 0.004) compared
to females, respectively. Leptin concentrations were higher in
females compared to males (33.4 ± 41.3 vs. 4.7 ± 7.5 ng/ml,
respectively, p < 0.001), however there were no differences
in the other adipokines or serum inflammatory markers (all
p > 0.1).
Demographic, anthropometric, and metabolic characteristics
of participants with and without back pain in the past month are
presented in Table 1. Twenty-four (39%) of participants reported
having back pain in the past month while the remaining 38
(61%) participants reported no back pain. Age and gender of
participants as well as physical activity (IPAQ-METs) were not
significantly different between those with and without back pain
(both p > 0.1; Table 1).
Back Pain and Anthropometric and
Cardiometabolic Parameters
Those who reported back pain in the past month had a
significantly higher BMI (p = 0.01), waist circumference
(p = 0.01), and fat mass (p = 0.04) compared to those without
back pain (Table 1). There were no differences between groups
in metabolic parameters including fasting glucose concentrations
or insulin sensitivity (both p > 0.1; Table 1). Similarly, SBP and
DBP as well as lipid profiles did not differ between those with and
without back pain in the past month (all p > 0.1; Table 1).
After adjustment for age and sex, higher BMI and waist
circumference remained significantly associated with back pain
(p = 0.02 for both), and trends were observed for higher
fat mass (p = 0.05) and fat-free mass (p = 0.08) (Table 1).
Associations between cardiometabolic parameters and back pain
remained non-significant after adjusting for age and sex (all p ≥
0.1, Table 1). Additional adjustment for fat mass, BMI, waist
circumference, or total % body fat did not alter the results (all
p ≥ 0.1; data not shown). There were no gender differences
in the relationships between any of the anthropometric or
cardiometabolic parameters and back pain (all p > 0.1 for gender
interactions; data not shown).
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TABLE 1 | Univariable and multivariable analyses for differences in demographic, anthropometric, and cardiometabolic parameters between those with and without back
pain in the past month.
Characteristics Back pain in the last month (n = 24) No back pain in the past month (n = 38) p1 or (95% CI) p2
Age (years) 30.3 ± 8.2 32.0 ± 8.8 0.4 – –
Females, n (%) 10 (41.7) 13 (34.2) 0.6 – –
IPAQ-METs score 1,665 (735–3,474) 2,375 (1,017–4,851) 0.7 1.0 (0.9–1.0) 0.6
ANTHROPOMETRIC PARAMETERS
Body mass index (kg/m2) 32.6 (29.1–37.0) 29.7 (27.6–31.5) 0.01 1.2 (1.0–1.3) 0.02
Waist circumference (cm) 109.6 ± 16.9 101.0 ± 9.3 0.01 1.1 (1.0–1.1) 0.02
Total body fat (%) 41.8 ± 9.3 39.3 ± 8.3 0.3 1.1 (0.9–1.2) 0.2
Fat mass (kg) 39.9 ± 12.3 33.9 ± 9.8 0.04 1.1 (1.0–1.1) 0.05
Fat-free mass (kg) 55.5 ± 15.1 52.1 ± 10.9 0.3 1.1 (1.0–1.1) 0.08
CARDIOMETABOLIC PARAMETERS
Fasting glucose (mmol/l) 4.7 ± 0.6 4.5 ± 0.5 0.2 2.4 (0.8–7.3) 0.1
Insulin sensitivity (mg/kg/min) 6.3 ± 3.1 6.6 ± 2.7 0.7 1.0 (0.8–1.2) 0.9
Systolic blood pressure (mmHg) 121.4 ± 14.5 121.6 ± 11.2 0.9 1.0 (0.9–1.1) 0.6
Diastolic blood pressure (mmHg) 80.9 ± 9.4 80.2 ± 8.5 0.8 1.0 (0.9–1.1) 0.6
Total cholesterol (mmol/l) 4.9 ± 0.9 5.0 ± 0.9 0.7 1.0 (0.5–1.7) 0.9
Triglycerides (mmol/l) 1.5 ± 0.6 1.6 ± 1.0 0.4 0.6 (0.1–8.1) 0.7
HDL cholesterol (mmol/l) 1.2 ± 0.3 1.2 ± 0.2 0.5 2.4 (0.3–19.6) 0.4
LDL cholesterol (mmol/l) 3.0 ± 0.9 3.1 ± 0.7 0.6 0.9 (0.4–1.9) 0.8
INFLAMMATORY MARKERS AND ADIPOKINES
hsCRP (mg/l) 3.0 (1.0–6.0) 1.4 (0.8–3.5) 0.3 1.9 (0.6–5.9) 0.2
TNF-α (pg/ml) 30.3 (16.3–60.4) 34.8 (21.2–72.9) 0.7 0.7 (0.2–2.2) 0.6
IL-6 (pg/ml) 27.2 (9.5–43.4) 21.2 (13.5–44.4) 0.8 0.8 (0.3–2.2) 0.6
IL-10 (pg/ml) 9.3 (6.4–13.6) 8.4 (6.8–17.0) 0.7 0.5 (0.1–3.9) 0.5
Adiponectin (ng/ml) 7,713 (2,885–14,516) 3,849 (2,348–9,915) 0.3 1.7 (0.7–4.5) 0.3
Adipsin (ng/ml) 744 (472–2,804) 721 (515–867) 0.04 1.1 (1.0–1.1) 0.03
Leptin (ng/ml) 5.5 (1.5–24.3) 2.3 (1.5–6.7) 0.05 3.2 (0.9–10.2) 0.05
Resistin (ng/ml) 0.4 (0.3–1.4) 0.5 (0.3–0.9) 0.9 1.0 (0.9–1.0) 0.9
Data presented as mean± SD or median (IQR) for non-normally distributed variables, unless otherwise specified. Non-normally distributed variables underwent logarithmic or square root
transformation to approximate normality prior to analyses. Bold figures indicate statistical significance. P1 = chi-squared tests or independent Student’s t-tests for differences between
groups in categorical and continuous variables, respectively; P2 = logistic regression adjusted for age and sex with back pain as dependent variable. IPAQ-METs, international physical
activity questionnaire-multiples of the resting metabolic rate; HDL/LDL, high/low-density lipoprotein; hsCRP, high sensitivity C-reactive protein; TNF-α, tumor necrosis factor-alpha; IL,
interleukin.
Back Pain and Serum Inflammatory
Markers and Adipokines
There were no differences between those with or without back
pain in the past month in cytokine concentrations including
hsCRP (p = 0.2), TNF-α (p = 0.6), IL-6 (p = 0.6), or IL-
10 (p = 0.5) (Table 1). Results remained non-significant after
adjusting for age and sex (all p > 0.1; Table 1), as well as after
further adjustment for any of the adiposity measures (all p > 0.1;
data not shown). There was no significant interaction by gender
in the relationships between back pain and any of these markers
(all p > 0.1 for interactions; data not shown).
Those who reported back pain in the past month had
significantly higher adipsin concentrations compared to those
reporting no back pain [median (IQR) = 744 (472–2,804) vs.
721 (515–867) ng/ml, respectively, p= 0.04;Table 1, Figure 1A].
Associations between adipsin and back pain remained significant
after adjusting for age and sex (p = 0.03; Table 1) as well as
after additional adjustment for any of the adiposity measures
including BMI, waist circumference, fat mass, or total % body fat
(all p ≤ 0.03; Table 2). In models which included age, sex, and
BMI or waist circumference, both BMI or waist circumference as
well as adipsin levels were associated with back pain (all p< 0.05;
data not shown).
A trend for higher leptin concentrations was observed in
participants who reported back pain in the past month compared
to those reporting no back pain [5.5 (1.5–24.3) vs. 2.3 (1.5–
6.7), respectively, p = 0.05; Table 1, Figure 1B]. This trend
persisted after adjustment for age and sex (p = 0.05; Table 1),
but was attenuated after further adjustment for BMI, waist
circumference, fat mass, or total % body fat (all p ≥ 0.1; Table 2).
In models which included age, sex, measures of adiposity, and
leptin concentrations, neither leptin concentrations nor adiposity
measures were associated with back pain (all p > 0.05; data not
shown).
Adiponectin and resistin concentrations did not differ
between groups in unadjusted analysis (p = 0.3 and p = 0.9,
respectively; Figures 1C,D) as well as after adjustment for age
and sex (p = 0.3 and p = 0.9, respectively; Table 1). Additional
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FIGURE 1 | Boxplots illustrating raw data for concentrations of adipsin (A), leptin (B), adiponectin (C), and resistin (D) in those with and without self-reported back
pain in the previous month. p = differences between groups using simple logistic regression after logarithmic or square root transformation to approximate normality.
adjustment for fat mass, BMI, waist circumference or total %
body fat did not alter the results (all p > 0.1; Table 2). There
were no gender differences in the relationships between any of
the adipokines and back pain (all p > 0.1 for gender interactions;
data not shown).
DISCUSSION
We report an association between serum adipsin concentrations
and self-reported back pain in the past month which was
independent of adiposity measures including BMI, waist
circumference, fat mass, or total % body fat. To our knowledge,
this is the first study to report an association between adipsin
and back pain in a metabolically well-characterized cohort of
overweight or obese, otherwise healthy adults. We also report
a trend for a relationship between leptin and back pain which
was attenuated after adjustment for adiposity. We confirm
previous studies that obesity is associated with back pain;
however no associations were observed between back pain and
cardiometabolic risk factors. Our findings suggest that adipsin
may be related to back pain independently of adiposity and
further studies are needed to determine if adipsin could be a novel
therapeutic target for prevention and/or treatment of back pain.
We report that individuals with back pain in the past month
had higher BMI, waist circumference, and fat mass compared
to those without back pain. This is consistent with previous
studies that have also shown greater levels of adiposity in
those with back pain (Urquhart et al., 2011; Chou et al.,
2016). There were no significant differences in cardiometabolic
parameters between those with and without back pain in the
past month. Few studies have examined the relationship between
cardiometabolic risk factors or the metabolic syndrome and
back pain (Ha, 2011; Duruöz et al., 2012; Suri et al., 2012;
Teraguchi et al., 2016). In a Japanese study of 928 adults, those
with one or more components of the metabolic syndrome had
higher odds of thoracic, but not lumbar spine, disc degeneration
determined by MRI, compared to those without any metabolic
syndrome components (Teraguchi et al., 2016). Conversely, in
435 participants from the Framingham Heart Study, diabetes,
hypercholesterolemia, and hypertension were not associated with
disc height loss on CT (Suri et al., 2012). However, both studies
did not collect data on back pain symptoms. Another study of
60 patients with lower back pain for ≥ 2 months found that 25%
had the metabolic syndrome (Duruöz et al., 2012). Similarly, in
1,085 Korean patients with chronic low back pain, the prevalence
of metabolic syndrome was relatively high at 36.2% (Ha, 2011).
Neither of these studies included participants without back pain,
hence no comparisons were made regarding the prevalence of
cardiometabolic risk factors between those with and without back
pain. Here, we show that in a well-characterized cohort of young,
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healthy adults, there were no differences in cardiometabolic risk
factors between those with and without back pain in the past
month.
We found no differences in inflammatory markers including
hsCRP, TNF-α, or IL-6 or −10 between those with or without
back pain in the past month. A population-based study using
National Health and Nutrition Examination Survey data from
15,322 people demonstrated that elevated CRP (>3.0 mg/dL)
was associated with greater odds of back pain, the odds further
increasing in those who were obese (Briggs et al., 2013). Similarly,
a cross-sectional study of 2,575 young adults found that higher
CRP was associated with an increased prevalence of back pain in
women (Shiri et al., 2008). Previous studies have also reported
elevated pro-inflammatory cytokines such as ILs-6, −7, and −8
in tissues of patients undergoing surgery for back pain (Altun,
2016; Zhang et al., 2016); associations between TNF-α, IL-6,
and IL-8 with back pain (Wang et al., 2008; Brinkley et al.,
2009; Kraychete et al., 2010; Pedersen et al., 2015; Queiroz
et al., 2017); and a possible key role for TNF-α and IL-1β in the
pathology of intervertebral disc degeneration (Li et al., 2014).
Whilst our study showed no differences in inflammatory marker
concentrations between those with or without back pain, this
was likely due to our small sample size and possible lack of
power to detect a significant difference. Notably, our study was
in healthy young adults, while some of the previous studies
were in elderly women (age ≥ 65 years) (de Queiroz et al.,
2016; Queiroz et al., 2017), who due to their advanced age, may
have higher levels of cytokines and inflammation (Franceschi
et al., 2007). Other studies were limited to participants with
existing chronic diseases or significant disability (Wang et al.,
2008; Brinkley et al., 2009), those undergoing surgery for back
pain (Altun, 2016; Zhang et al., 2016), or who were recruited
from large tertiary-care hospitals (Pedersen et al., 2015).
These populations may have elevated levels of inflammatory
markers which may, in part, explain the discrepancy with
our findings since participants in our study were healthy
individuals without existing comorbidities or underlying
inflammation.
We report the novel finding that back pain in the past
month was associated with higher adipsin concentrations, with
a trend also observed for a relationship with higher leptin
concentrations. Adipokines such as leptin and adipsin are
reported to be involved in appetite and weight maintenance,
but also have inflammatory and nociceptive properties (Fantuzzi,
2005; Lim et al., 2009). Leptin is thought to have a role in
neuropathic pain (Lim et al., 2009) and pain in knee, hip,
and hand osteoarthritis (Clockaerts et al., 2010; Massengale
et al., 2012; Lübbeke et al., 2013). Increased leptin is directly
associated with obesity and is suspected to be involved in
reorganizing the cytoskeleton of nucleus pulposus cells, thereby
altering disc organization and structure (Samartzis et al., 2013).
Indeed, in vitro studies have reported a role for leptin in disc
degeneration (Zhao et al., 2008; Samartzis et al., 2013; Segar
et al., 2016), and leptin is proposed as a causative link between
obesity and osteoarthritis (Hui et al., 2012; Vuolteenaho et al.,
2014). However, few epidemiological studies have explored the
association between leptin and back pain, with inconsistent
Frontiers in Physiology | www.frontiersin.org 6 February 2018 | Volume 9 | Article 93
Brady et al. Back Pain and Adipokines in Obesity
findings. In a study of 104 patients with back pain and 52
healthy controls, those with back pain had lower leptin levels
compared to controls (Lippi et al., 2017). Conversely, a larger
cross-sectional study of 2,575 young Finnish adults found that
the prevalence of back pain increased with increasing serum
leptin in women (Shiri et al., 2008). Here, we report a trend
for increased leptin levels in those with back pain, which is
attenuated after adjustment for adiposity. Our findings suggest
that associations between leptin and back pain may be a result
of underlying adiposity, particularly fat mass, which has seldom
been measured in previous studies (Shiri et al., 2008). Further
large-scale studies are needed to confirm the direction and
magnitude of the relationship between leptin and back pain,
and to determine whether this relationship may be mediated by
adiposity.
In contrast, our findings showed that adipsin was associated
with back pain in the past month independently of any measure
of adiposity. Although thought to have pro-inflammatory
properties, adipsin has been poorly studied in relation to bone
health and osteoarthritis. One study which measured adipsin
and leptin in 138 patients found that both adipsin and leptin
levels predicted greater knee cartilage volume loss over time, and
were associated with higher incidence of total knee replacement
(Martel-Pelletier et al., 2016). Authors hypothesized that joint
inflammation in knee osteoarthritis may induce an increase in
leptin concentrations and, secondarily, catabolic factors such
as adipsin, leading to cartilage degradation and loss (Martel-
Pelletier et al., 2016). Similarly, in genomic studies, higher adipsin
levels were associated with moderate and severe osteoarthritis
(Fernández-Puente et al., 2011). Adipsin is known to act as
a serine protease (regulator of bone remodeling) and to be
a component of the alternative complement pathway (which
activates innate immune responses) (Martel-Pelletier et al., 2016);
however, no study has yet reported its biological or molecular
effects in articular tissues.Moreover, to our knowledge, no studies
have examined the relationship between adipsin and back pain.
Here, we show for the first time that higher adipsin levels were
related to back pain in overweight or obese, otherwise healthy
adults, independently of adiposity, which is consistent with
previous studies of higher adipsin in knee osteoarthritis (Martel-
Pelletier et al., 2016). Collectively, these findings suggest that
adipsin may be involved in the pathophysiology of osteoarthritis
or back pain through a systemic inflammatory pathway unrelated
to obesity. However, further studies are needed to confirm the
role of adipsin in back pain and to determine its underlying
mechanisms.
This study has some limitations. The cross-sectional nature
of the study means we cannot establish causality or determine
whether changes in anthropometric or cardiometabolic
parameters may affect back pain longitudinally. Because the
data used was from a previous RCT, back pain was not the
primary outcome and there was no formal power calculation.
Hence, our sample size was likely underpowered to detect
differences in cardiometabolic parameters or inflammatory
markers such as hsCRP between those with or without back
pain. The study was not designed to assess back pain as a
primary outcome and we were only able to determine back
pain using a single question. This limits the precision of the
study in determining the severity or degree of disability caused
by back pain, or in defining subgroups of participants with
severe or chronic back pain. Use of a validated questionnaire
such as the Roland-Morris Disability Questionnaire or the
Waddell Disability Index may therefore have yielded different
results. The sample comprised overweight or obese, otherwise
healthy adults, hence we were unable to compare our findings
between overweight/obese and lean individuals and our results
may not be generalizable to other populations including lean
adults or those with existing comorbidities or osteoarthritic
conditions.
Nevertheless, this study is to our knowledge the first to report
a relationship between back pain and novel adipokines such
as adipsin. We were able to show that adipsin was associated
with back pain independently of adiposity, which has not been
previously reported. We included a well-characterized cohort of
overweight or obese, otherwise healthy adults, where there was no
confounding by diseases status, comorbidities, or medication use.
Gold-standard measures of cardiometabolic risk were employed,
including DEXA for body composition, and hyperinsulinaemic-
euglycaemic clamp for insulin sensitivity.
To conclude, despite higher rates of obesity in those with
back pain, we found similar cardiometabolic risk profiles between
those with and without back pain in the past month. However,
adipsin and leptin concentrations were higher in those with back
pain, and adipsin was associated with back pain independently of
adiposity. Our findings provide new insights into the metabolic
and inflammatory profiles of those with back pain, and highlight
the need for larger studies to determine if adipsin could be
a novel therapeutic target for prevention and/or treatment of
back pain.
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